S_mnuary We examined DNA from 116 female and four male breast cancer patients for loss of heterozygosity (LOH). DNA was analysed by polymerase chain reaction using ten microsatellite markers on chromosome 11. Three distinct regions of LOH were identified: lIpl5.5, 11q13 and lq22-qter with a LOH frequency of 19, 23 and 37-43% respectively. The marker DllS%9 showing the highest frequency of LOH (43%) (Mackay et al., 1988), 17q and 18q (Cropp et al., 1990) .
The majority (approximately 90%) of breast cancer cases are considered to be sporadic. Multiple genetic alterations accumulating in cells result in alterations of normal growth control. Characterisation of the genes that play a role in this tumongenic process is a necessary step towards understanding it. Mapping the chromosomal regions that are altered in breast cancer cells has proven to be a powerful way of locating these genes. Deletion and gene activation are known to be the most frequent genetic changes in breast cancer cells. Chromosomal translocations may also be involved in the development of breast cancer, as suggested by Lindblom et al. (1994) , who showed that the constitutional llq;22q translocation predisposes to breast cancer. Chromosomal regions that are known to be amplified in breast cancer are 8q (Escot et al., 1986) , 1 1q13 (Varley et al., 1988 ), 17q (Yokota et al., 1986 ) and 20q (Kalliomemi et al., 1994) . Regions with frequent LOH in breast cancer are lp (Genuardi et al., 1989) , lq (Chen et al.. 1989), 3p (Eiriksdottir et al., 1995) , 6q (Devilee et al., 1991) , I lpl5 (Ali et al., 1987) , 13q (Lundberg et al.. 1987 ), 16q (Sato et al., 1990 , 17p (Mackay et al., 1988), 17q and 18q (Cropp et al., 1990) .
Chromosome 11 has been shown to possess the Wilms' tumour 1 gene (WTI) on the p-arm (Madden et al., 1991) . The MEN-I locus has been mapped to the 1lql3 region (Larsson et al., 1988) and the ataxia telangiectasia (AT) genes have been mapped to the 1lq22-23 region (Gatti et al., 1988) . Epidemiological studies suggest that heterozygous AT carriers may be predisposed to cancer (Swift et al., 1991) . The relative risk for breast cancer has been estimated to be 5-fold greater in women carrying the AT gene(s) than in the normal population. Cytological and LOH studies have described aberrations on chromosome 1lq22-q23 in breast cancer (Ferti-Passantonopoulo et al., 1991; Carter et al., 1994) .
Studies on cancer cell lines (e.g. MCF-7) have shown that chromosome 11 suppresses tumorigenicity when injected into cells lacking a normal chromosome 11 . The long arm of chromosome 11 suppresses tumorigenicity of HeLa cells (Misra and Srivatsan, 1989) , suggesting a tumour-suppressor gene on llq. Varley et al., 1988) . The results presented here confirm that one additional region on chromosome 11 (1 1q22-qter) is altered in breast cancer (Carter et al., 1994) . The regions showing the highest frequency of LOH were lIp 15, 1 1q22-q23.3 and 1 1q24-qter. In some tumours these were the only regions found to be altered (Figure 2 ). Frequent LOH telomeric to 1 1q23 has not been described previously in breast cancer. Whether the 1lq22-q23.3 and 1lq24-qter regions are both target regions for deletion or whether one is only a subregion of the other remains to be shown. A fine-scale microsatellite mapping in a larger number of tumour samples could provide information necessary to answer this question.
We could not detect amplification at the 1lq22-qter region by Southern analysis. Therefore we conclude that the LOH detected by the microsatellite markers are deletions. This region is also frequently found to be deleted in ovarian cancer (Foulkes et al., 1993 (Kapp et al., 1992) . Epidemiological studies have suggested that AT carriers are at a 5-fold risk of breast cancer (Swift et al., 1991 (Magdelenat et al., 1994) . A possible explanation could be that having one copy of these hormone receptor genes is sufficient for the cells and also that a strong selection exists against mutations in these genes.
A significant correlation has been described by Takita et al. (1992) and Carter et al. (1994) between LOH at 17pl3 and LOH at chromosome 11 (llpl5 and 1lq22-q23 respectively). Our results showed no significant association between LOH at chromosome 11 and 17p. On the other hand a highly significant association was found between LOH at lp 15 and LOH at 17q21 and 3p, which is interesting in our opinion in view of the location of the BRCAJ gene at 17q21. Eiriksdottir et al. (1995) found LOH at chromosome 3p to be a significant prognostic variable for overall survival of breast cancer patients. The significant association between LOH at llpl5 and 3p could therefore have some prognostic value. Although only a few samples were examined, the incidence of LOH at chromosome 1 lq in male breast cancer is of interest. We think therefore that further investigations at the 1 I q region should be made with more samples of male breast cancer cases.
Chromosome 11 has been shown to suppress malignancy in cell hybrids. This supports the idea that chromosome 11 includes tumour suppressor gene(s). Introduction of the qarm of chromosome 11 into HeLa cells was shown to suppress malignancy (Misra and Srivatsan, 1989) . When a whole chromosome 11 was transferred into an MCF-7 breast cancer cell line, tumorigenicity was suppressed. Further refinement of tumour-suppressor gene(s) location implied the possibility of two genes, at IlplS.5 and llql3-q23 . These conclusions were based upon the frequent findings of LOH on llpl5.5. Our results suggest that the 1 lq23-qter region may be just as likely to contain the suppressor of malignancy. Both of these regions (i.e. llpl5.5 and llq23-qter) were deleted in a subclone of MCF-7 cells that still possessed malignancy . A tumour suppressor gene might also be localised to the common region (1 lq22-q23) of these two studies and the present one) because the MCF-7 cells that retained this region had lower tumorigenicity. The possibility of two suppressor genes, located at the llq22-q23.3 and q24-qter region, should therefore not be excluded.
